# Nuclide record idea-tb161-instead-of-lu177 (idea). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/ideas/idea-tb161-instead-of-lu177/>
  a schema:CreativeWork ;
  nuclide:kind "idea" ;
  schema:identifier "idea-tb161-instead-of-lu177" ;
  schema:name "Terbium-161 instead of lutetium-177 in the same ligands"@en ;
  schema:description "Terbium-161 is a close chemical cousin of lutetium-177 that, as well as giving off the same kind of radiation, also releases a shower of extremely short-range electrons. In theory that extra radiation could finish off single cancer cells and tiny clusters that a lutetium-177 treatment might miss, using the same targeting molecules already in use."@en ;
  schema:url <https://nuclide.cc/ideas/idea-tb161-instead-of-lu177/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www.urotoday.com/video-lectures/2025-ucsf-ucla-psma-conference/video/4752-beyond-lutetium-psma-exploring-terbium-161-for-treatment-resistant-prostate-cancer-presentation-michael-hofman.html>, <https://pubmed.ncbi.nlm.nih.gov/39978166/>, <https://link.springer.com/article/10.1007/s00259-023-06316-y>, <https://pmc.ncbi.nlm.nih.gov/articles/PMC12629902/> ;
  nuclide:tag "prostate", "isotope alternative", "auger electrons" ;
  nuclide:related <https://nuclide.cc/technologies/lu177-radioligand-therapy/>, <https://nuclide.cc/technologies/prrt/>, <https://nuclide.cc/technologies/radioligand-dosimetry/>, <https://nuclide.cc/technologies/psma-pet/>, <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/tb-161/> .